Results from a recent Yale Cancer Center Phase II trial studying ixabepilone and bevacizumab vs ixabepilone alone in platinum resistant ovarian cancer patients have led to the combination added as a Category 2B recommended regimen in Ovarian Cancer (Version 1.2023) of the National Comprehensive Cancer Network (NCCN) Guidelines®.
The results of the study, which was authored by Alessandro Santin, MD, Professor of Obstetrics, Gynecology & Reproductive Sciences, and Co-Chief, Section of Gynecologic Oncology, and Elena Ratner, MD, Professor of Obstetrics, Gynecology & Reproductive Sciences, and Co-Chief, Section of Gynecologic Oncology, were published in the British Journal of Cancer and represent ‘a well-tolerated regimen with encouraging activity.’
“The new standard of care for platinum resistant ovarian cancer is great news as another treatment option is now available for patients with platinum-resistant disease,” said Dr. Santin. “I would like to thank all co-authors of this paper as well as the gynecologic oncology personnel in our Clinical Trials Office that worked so hard to enroll patients and complete the Yale Investigator-Initiated Trial.”
NCCN Guidelines® are the recognized standard for clinical direction and policy in cancer care. The latest updates for ovarian cancer were released in December, 2022.